MODY 3

From WikiMD's WELLNESSPEDIA


MODY 3
Synonyms Maturity onset diabetes of the young type 3
Pronounce N/A
Specialty N/A
Symptoms Hyperglycemia, polyuria, polydipsia, weight loss
Complications Diabetic retinopathy, nephropathy, neuropathy
Onset Typically in adolescence or early adulthood
Duration Chronic
Types N/A
Causes Genetic mutation in the HNF1A gene
Risks Family history of diabetes
Diagnosis Genetic testing, blood glucose tests
Differential diagnosis Type 1 diabetes, Type 2 diabetes
Prevention N/A
Treatment Dietary management, oral hypoglycemic agents
Medication Sulfonylureas, insulin (if necessary)
Prognosis Variable, depending on management
Frequency Accounts for 1-2% of all diabetes cases
Deaths N/A


MODY 3 is a form of Maturity onset diabetes of the young (MODY), which is a group of inherited forms of diabetes mellitus. It is caused by mutations in the HNF1A gene.

Overview[edit]

MODY 3 is the most common form of MODY. It is characterized by an onset usually before the age of 25, a primary defect in insulin secretion and a strong inheritance pattern. The disease is caused by mutations in the HNF1A gene, which encodes a transcription factor that regulates the expression of several liver-specific genes.

Symptoms[edit]

The symptoms of MODY 3 are similar to those of other forms of diabetes, including frequent urination, excessive thirst, fatigue, blurred vision, and weight loss. However, MODY 3 often goes undiagnosed because the symptoms are mild or absent.

Diagnosis[edit]

The diagnosis of MODY 3 is based on clinical features and genetic testing. The presence of diabetes in multiple generations, the onset of diabetes at a young age, and the absence of obesity or other risk factors for type 2 diabetes suggest the diagnosis of MODY 3.

Treatment[edit]

The treatment of MODY 3 involves lifestyle modifications and medication. Patients with MODY 3 often respond well to low doses of sulfonylureas, which stimulate the release of insulin from the pancreas.

Prognosis[edit]

The prognosis of MODY 3 is generally good, but patients are at risk for long-term complications of diabetes, including heart disease, kidney disease, and eye disease.

See also[edit]

References[edit]



Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Medical weight loss NYC | Affordable GLP-1 injections NYC | Budget GLP-1 weight loss shots Philadelphia | New Jersey medical weight loss | NYC medical weight loss | Philadelphia medical weight loss | Sleep clinic NYC | W8MD's Philadelphia GLP-1 doctor | Weight loss prescriptions NYC

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.